Sanofi’s Toujeo Is Approved, Now The Hard Part: Commercialization

Sanofi’s next-generation long-acting insulin will compete against an entrenched rival, the company’s own Lantus – a challenging proposition for any drug marketer, especially in the increasingly cost-conscious diabetes sector.